Lasix: adverse event reports filed with FDA

12,591

reports as suspect product

0.1% of all reports · about 560 a year

244

reports, 12 months to June 2026

373 in the 12 months before

86.2%

marked serious by the reporter

93.4% across the class

11.4%

record death among outcomes, as reported

1,437 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Lasix reports recording the termmedian drug in loop diuretic

1. Dyspnoeashortness of breath9.7%1,225
2. Hypotensionlow blood pressure8.6%1,078
3. Dehydrationdehydration7%885
4. Hyponatraemialow blood sodium5.5%692
5. Renal failure acute5.2%654
6. Dizzinesslight-headedness or unsteadiness5%624
7. Nauseafeeling sick4.9%614
8. Astheniaweakness or lack of energy4.9%612
9. Falla fall4.8%605
10. Hypokalaemialow blood potassium4.8%605
11. Diarrhoealoose or frequent stools4.7%593
12. Drug ineffectivethe medicine did not work as expected4.6%575
13. Fatiguetiredness4.5%572
14. Syncopefainting4.5%570
15. Drug interactionan interaction between medicines4.4%558
16. Oedema peripheralswelling of the legs, ankles or hands4.1%510
17. Acute kidney injurysudden loss of kidney function3.9%488
18. Renal failurekidney failure3.9%488
19. Weight decreasedweight loss3.7%470
20. Vomitingbeing sick3.7%465
21. Hyperkalaemiahigh blood potassium3.6%456
22. Condition aggravatedthe condition being treated got worse3.6%450
23. Malaisegeneral feeling of being unwell3.4%433
24. Headachehead pain3.4%430
25. Blood creatinine increasedraised creatinine, a kidney test3.4%422
26. Cardiac failureheart failure3.2%405
27. Weight increasedweight gain3.1%389
28. Pneumonialung infection3.1%386
29. Cardiac failure congestivecongestive heart failure3%379
30. Peripheral swellingswelling of the arms or legs3%374

Top 30 of 1,851 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 5 drugs in the loop diuretic class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 69,262 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 38.2% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 12,591 reports.

Drugs most often listed in the same reports

Other products listed in reports where Lasix is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the loop diuretic class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Lasix as a suspect or interacting product; reports listing it only as a concomitant medication (131,867) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.